Loading...
•
Mar 31, 2025
Aytu BioScience Q3 2025 Earnings Report
Aytu BioPharma reported strong revenue growth and turned a profit in Q3 2025.
Key Takeaways
Aytu BioPharma achieved 32% revenue growth year-over-year in Q3 2025, driven by robust performance in both its ADHD and Pediatric portfolios. The company reported net income of $4.0 million and adjusted EBITDA of $3.9 million, reflecting successful execution of its strategic realignment and cost optimization efforts.
Total revenue grew 32% year-over-year to $18.5 million.
Net income reached $4.0 million, compared to a $2.9 million loss in the prior year period.
The ADHD Portfolio contributed $15.4 million in revenue, growing 25% year-over-year.
Cash and cash equivalents stood at $18.2 million at quarter-end after debt repayments.
Forward Guidance
The company will continue focusing on expanding its prescription portfolio and leveraging operational efficiencies to drive profitability and cash flow.
Positive Outlook
- Ongoing growth in ADHD and Pediatric portfolios.
- Streamlined operations reduced operating expenses by 13% YoY.
- Continued paydown of long-term debt.
- Expanded utilization of Aytu RxConnect platform.
- Positioned for positive cash flow generation.
Challenges Ahead
- Gross margin decreased to 69% due to temporary inventory costs.
- ADHD portfolio margins impacted by production transition.
- Revenue still concentrated in two main therapeutic areas.
- Limited revenue contribution from other or discontinued products.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...